2ND-LINE TREATMENT WITH IFOSFAMIDE AND CARBOPLATIN IN PATIENTS WITH OVARIAN-CARCINOMA RELAPSING AFTER TREATMENT WITH CARBOPLATIN

被引：4

作者：

DOBBS, SP ^{[1
]}

GRIBBIN, C ^{[1
]}

CHAN, SY ^{[1
]}

BESSELL, EM ^{[1
]}

机构：

[1] CITY HOSP,DEPT CLIN ONCOL,NOTTINGHAM NG5 1PB,ENGLAND

来源：

EUROPEAN JOURNAL OF CANCER | 1994年 / 30A卷 / 01期

关键词：

D O I：

10.1016/S0959-8049(05)80013-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

20 patients with ovarian carcinoma whose disease had relapsed (1-42 months, median 4 months) after showing either response or stable disease to carboplatin, were treated with ifosfamide (5 g/m(2) intravenously over 24 h, day 1) and carboplatin (200 mg/m(2) intravenously day 2) as second-line treatment. The mean number of treatment cycles was 3.5 (range 1-6). The major toxicities were thrombocytopenia (WHO grade 3/4, 25%), neutropenia (WHO grade 3/4, 40%) and encephalopathy (WHO grade 3/4, 15%). Overall response rate was 15% [complete response, 0; partial response, 3 (15%); no change, 5 (25%) and progressive disease, 12 (60%)]. The median survival from the date of second-line treatment was 7 months. This combination offers no advantage over either agent used alone.

引用

页码：30 / 33

页数：4

共 13 条

[1] RESPONSE OF PATIENTS IN PHASE-II STUDIES OF CHEMOTHERAPY IN OVARIAN-CANCER - IMPLICATIONS FOR PATIENT TREATMENT AND THE DESIGN OF PHASE-II TRIALS [J].